Browsing Category
Dry Powder Inhalers (DPI)
Efavirenz dissolution enhancement III: Colloid milling, pharmacokinetics and electronic tongue…
03. January 2017
Abstract
Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), is part of first-line therapy for the treatment of human immunodeficiency virus type 1 infection (HIV-1/AIDS). This drug shows relatively low oral absorption and bioavailability, as…
Read More...
Read More...
EXCIPURE – Lactose Solutions for Dry Powder Inhalation – launched by Armor Pharma
18. November 2016
EXCIPURE - Lactose Solutions for Dry Powder Inhalation - launched by Armor Pharma
Read More...
Read More...
Development of controlled-release cisplatin dry powders for inhalation against lung cancers
18. October 2016 Abstract The present study focuses on the development of dry powders for inhalation as adjuvant chemotherapy in lung cancer treatment. Cisplatin was chosen as a potential candidate for a local treatment as it…
Read More...
Read More...
New aspects of developing a dry powder inhalation formulation applying the quality-by-design…
10. July 2016 Abstract The current work outlines the application of an up-to-date and regulatory-based pharmaceutical quality management method, applied as a new development concept in the process of formulating dry powder…
Read More...
Read More...
Lactose Excipients by Armor Pharma
15. April 2015
Our quest for excellence has led us to a sustainable level of product development : a structured range of lactose for the formulation of Oral Solid Dosage Forms and Dry Powder Inhalers, which meets Ph. Eur., USP-NF, JP monographs.
ARMOR…
Read More...
Read More...